Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Dec;70(6):1203–1210. doi: 10.1038/bjc.1994.474

Treatment of multiple myeloma according to the extension of the disease: a prospective, randomised study comparing a less with a more aggressive cystostatic policy. Cooperative Group of Study and Treatment of Multiple Myeloma.

A Riccardi 1, G Ucci 1, R Luoni 1, S Brugnatelli 1, O Mora 1, R Spanedda 1, A De Paoli 1, L Barbarano 1, M Di Stasi 1, F Alberio 1, et al.
PMCID: PMC2033710  PMID: 7981078

Abstract

The purpose of the study was to ascertain whether the prognostic significance of staging in multiple myeloma (MM) is influenced by the aggressiveness of effective induction treatment and/or by continuing or discontinuing maintenance chemotherapy. Patients with untreated stage I MM (defined according to Durie and Salmon) were randomised between being followed without cytostatics until the disease progressed and receiving six courses of melphalan and prednisone (MP-P) just after diagnosis; stage II patients were uniformly treated with MPH-P and stage III patients were randomised between MPH-P and four courses of combination chemotherapy with Peptichemio, vincristine and prednisone (PTC-VCR-P). Within each stage, responsive patients were randomised between receiving additional therapy only until maximal tumour reduction was reached (plateau phase) and continuing induction therapy indefinitely until relapse. With resistant, progressive or relapsing disease, patients originally treated with MPH-P for induction received combination chemotherapy and vice versa. The overall first response rate was 43.8% (42.2% in 206 stage I, II and III patients treated with MPH-P and 48.0% in 75 stage III patients treated with combination chemotherapy, P = NS). Combination chemotherapy was more myelotoxic than MPH-P and, in particular, caused more non-haematological side-effects. Both the less and the more aggressive induction policies gave the same disease control. Progression of disease was statistically similar in stage I patients who were initially left untreated and in t hose who received MPH-P just after diagnosis; median duration of first response was similar in stage III patients receiving MPH-P and in those on combination chemotherapy. In all stages, discontinuing or continuing maintenance did not alter the median duration of first response. The overall second response rate was 28.5% (34.0% to MPH-P and 25.3% to combination chemotherapy, P = NS). Median survival was greater than 78 months in stage I, was 46.3 months in stage II and was 24.3 months in stage III patients, still independent of both induction and post-induction policies. In MM, the significance of staging for survival is independent of both the aggressiveness of induction and of continuing or discontinuing maintenance chemotherapy after the maximal tumor reduction has been achieved. Both MPH-P and and the association of PTC, VCR and P are effective in inducing first response and also second response in patients failing on the alternative regimen, but PTC-VCR-P causes more side effects. Thus, the overwhelming majority of patients with MM can safely be given MPH-P as first therapy, and this treatment may be delayed in early diseases.

Full text

PDF
1203

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abramson N., Lurie P., Mietlowski W. L., Schilling A., Bennett J. M., Horton J. Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma. Cancer Treat Rep. 1982 Jun;66(6):1273–1277. [PubMed] [Google Scholar]
  2. Alexanian R., Gehan E., Haut A., Saiki J., Weick J. Unmaintained remissions in multiple myeloma. Blood. 1978 Jun;51(6):1005–1011. [PubMed] [Google Scholar]
  3. Belch A., Shelley W., Bergsagel D., Wilson K., Klimo P., White D., Willan A. A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. Br J Cancer. 1988 Jan;57(1):94–99. doi: 10.1038/bjc.1988.17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bergsagel D. E., Bailey A. J., Langley G. R., MacDonald R. N., White D. F., Miller A. B. The chemotherapy on plasma-cell myeloma and the incidence of acute leukemia. N Engl J Med. 1979 Oct 4;301(14):743–748. doi: 10.1056/NEJM197910043011402. [DOI] [PubMed] [Google Scholar]
  5. Boccadoro M., Marmont F., Tribalto M., Avvisati G., Andriani A., Barbui T., Cantonetti M., Carotenuto M., Comotti B., Dammacco F. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. J Clin Oncol. 1991 Mar;9(3):444–448. doi: 10.1200/JCO.1991.9.3.444. [DOI] [PubMed] [Google Scholar]
  6. Boros L., Chuang C., Butler F. O., Bennett J. M. Leukemia in Rochester (NY). A 17-year experience with an analysis of the role of cooperative group (ECOG) participation. Cancer. 1985 Nov 1;56(9):2161–2169. doi: 10.1002/1097-0142(19851101)56:9<2161::aid-cncr2820560904>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  7. Buzaid A. C., Durie B. G. Management of refractory myeloma: a review. J Clin Oncol. 1988 May;6(5):889–905. doi: 10.1200/JCO.1988.6.5.889. [DOI] [PubMed] [Google Scholar]
  8. Cavagnaro F., Lein J. M., Pavlovsky S., Becherini J. O., Pileggi J. E., Micheo E. Q., Jait C., Musso A., Suárez A., Pizzolato M. Comparison of two combination chemotherapy regimens for multiple myeloma: methyl-CCNU, cyclophosphamide, and prednisone versus melphalan and prednisone. Cancer Treat Rep. 1980 Jan;64(1):73–79. [PubMed] [Google Scholar]
  9. Cavo M., Gobbi M., Tura S. Peptichemio in multiple myeloma. (Preliminary results). Haematologica. 1981 Apr;66(2):208–215. [PubMed] [Google Scholar]
  10. Cohen H. J., Silberman H. R., Larsen W. E., Johnson L., Bartolucci A. A., Durant J. R. Combination chemotherapy with intermittent 1-3-bis(2-chloroethyl)1-nitrosourea (BCNU), cyclophosphamide, and prednisone for multiple myeloma. Blood. 1979 Oct;54(4):824–836. [PubMed] [Google Scholar]
  11. Cooper M. R., McIntyre O. R., Propert K. J., Kochwa S., Anderson K., Coleman M., Kyle R. A., Prager D., Rafla S., Zimmer B. Single, sequential, and multiple alkylating agent therapy for multiple myeloma: a CALGB Study. J Clin Oncol. 1986 Sep;4(9):1331–1339. doi: 10.1200/JCO.1986.4.9.1331. [DOI] [PubMed] [Google Scholar]
  12. Durie B. G., Salmon S. E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975 Sep;36(3):842–854. doi: 10.1002/1097-0142(197509)36:3<842::aid-cncr2820360303>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  13. Gahrton G., Tura S., Ljungman P., Belanger C., Brandt L., Cavo M., Facon T., Granena A., Gore M., Gratwohl A. Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med. 1991 Oct 31;325(18):1267–1273. doi: 10.1056/NEJM199110313251802. [DOI] [PubMed] [Google Scholar]
  14. Gregory W. M., Richards M. A., Malpas J. S. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol. 1992 Feb;10(2):334–342. doi: 10.1200/JCO.1992.10.2.334. [DOI] [PubMed] [Google Scholar]
  15. Harley J. B., Pajak T. F., McIntyre O. R., Kochwa S., Cooper M. R., Coleman M., Cuttner J. Improved survival of increased-risk myeloma patients on combined triple-alkylating-agent therapy: a study of the CALGB. Blood. 1979 Jul;54(1):13–22. [PubMed] [Google Scholar]
  16. Hjorth M., Hellquist L., Holmberg E., Magnusson B., Rödjer S., Westin J. Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. The Myeloma Group of Western Sweden. Br J Haematol. 1990 Feb;74(2):185–191. doi: 10.1111/j.1365-2141.1990.tb02564.x. [DOI] [PubMed] [Google Scholar]
  17. Hjorth M., Hellquist L., Holmberg E., Magnusson B., Rödjer S., Westin J. Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I--a randomized study. Myeloma Group of Western Sweden. Eur J Haematol. 1993 Feb;50(2):95–102. doi: 10.1111/j.1600-0609.1993.tb00148.x. [DOI] [PubMed] [Google Scholar]
  18. Kildahl-Andersen O., Bjark P., Bondevik A., Bull O., Burgess G., Dehli O., Hoel S., Jaeger S., Kvambe V., Mürer F. Multiple myeloma in central and northern Norway 1981-1982: a follow-up study of a randomized clinical trial of 5-drug combination therapy versus standard therapy. Eur J Haematol. 1988 Jul;41(1):47–51. doi: 10.1111/j.1600-0609.1988.tb00867.x. [DOI] [PubMed] [Google Scholar]
  19. MacLennan I. C., Chapman C., Dunn J., Kelly K. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults. Lancet. 1992 Jan 25;339(8787):200–205. doi: 10.1016/0140-6736(92)90004-m. [DOI] [PubMed] [Google Scholar]
  20. MacLennan I. C., Cusick J. Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Medical Research Council Working Party on Leukaemia in Adults. Br J Cancer. 1985 Aug;52(2):153–158. doi: 10.1038/bjc.1985.171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. MacLennan I. C., Kelly K., Crockson R. A., Cooper E. H., Cuzick J., Chapman C. Results of the MRC myelomatosis trials for patients entered since 1980. Hematol Oncol. 1988 Apr-Jun;6(2):145–158. doi: 10.1002/hon.2900060215. [DOI] [PubMed] [Google Scholar]
  22. Merlini G., Gobbi P. G., Riccardi A., Riva G., Sardi C., Perugini S. Peptichemio induction therapy in myelomatosis. Cancer Chemother Pharmacol. 1982;8(1):9–16. doi: 10.1007/BF00292864. [DOI] [PubMed] [Google Scholar]
  23. Merlini G., Riccardi A., Riccardi P. G., Montecucco C. M., Pavesi F., Ascari E. Peptichemio, vincristine, prednisone induction treatment in multiple myeloma. Tumori. 1985 Dec 31;71(6):581–588. doi: 10.1177/030089168507100611. [DOI] [PubMed] [Google Scholar]
  24. Monconduit M., Menard J. F., Michaux J. L., Le Loet X., Bernard J. F., Grosbois B., Pollet J. P., Azais I., Laporte J. P., Doyen C. VAD or VMBCP in severe multiple myeloma. The Groupe d'Etudes et de Recherche sur le Myélome (GERM). Br J Haematol. 1992 Feb;80(2):199–204. doi: 10.1111/j.1365-2141.1992.tb08901.x. [DOI] [PubMed] [Google Scholar]
  25. Montecucco C., Riccardi A., Merlini G., Ascari E. Complete remission in plasma cell leukaemia. Br J Haematol. 1986 Mar;62(3):525–527. doi: 10.1111/j.1365-2141.1986.tb02964.x. [DOI] [PubMed] [Google Scholar]
  26. Montecucco C., Riccardi A., Merlini G., Mazzini G., Giordano P., Danova M., Ascari E. Plasma cell DNA content in multiple myeloma and related paraproteinemic disorders. Relationship with clinical and cytokinetic features. Eur J Cancer Clin Oncol. 1984 Jan;20(1):81–90. doi: 10.1016/0277-5379(84)90038-5. [DOI] [PubMed] [Google Scholar]
  27. Peest D., Deicher H., Coldewey R., Schmoll H. J., Schedel I. Induction and maintenance therapy in multiple myeloma: a multicenter trial of MP versus VCMP. Eur J Cancer Clin Oncol. 1988 Jun;24(6):1061–1067. doi: 10.1016/0277-5379(88)90160-5. [DOI] [PubMed] [Google Scholar]
  28. Riccardi A., Giordano M., Girino M. Treatment of adult acute non-lymphoblastic leukemia: a computer-aided analysis. Haematologica. 1987 Jan-Feb;72(1):71–88. [PubMed] [Google Scholar]
  29. Riccardi A., Gobbi P. G., Ucci G., Bertoloni D., Luoni R., Rutigliano L., Ascari E. Changing clinical presentation of multiple myeloma. Eur J Cancer. 1991;27(11):1401–1405. doi: 10.1016/0277-5379(91)90020-e. [DOI] [PubMed] [Google Scholar]
  30. Riccardi A., Martinotti A., Perugini S. Cytokinetic changes in two cases of plasma leukemia treated with a multipeptide derivative of m-[di(2-chloroethyl)amino]-L-phenylalanine (Peptichemio). Eur J Cancer. 1978 Oct;14(10):1099–1106. doi: 10.1016/0014-2964(78)90065-8. [DOI] [PubMed] [Google Scholar]
  31. Riccardi A., Merlini G., Montecucco C., Danova M., Ucci G., Cassano E., Ascari E. Peptichemio, vincristine and prednisone versus melphalan and prednisone as induction therapy in multiple myeloma. Eur J Cancer Clin Oncol. 1986 Jul;22(7):787–791. doi: 10.1016/0277-5379(86)90364-0. [DOI] [PubMed] [Google Scholar]
  32. Riccardi A., Montecucco C., Danova M., Ucci G., Merlini G., Ascari E. Rate of M-component changes and plasma cell labeling index in 25 patients with multiple myeloma treated with peptichemio. Cancer Treat Rep. 1985 Sep;69(9):971–975. [PubMed] [Google Scholar]
  33. Riccardi A., Montecucco C., Merlini G., Ucci G., Cremonini N., Gobbi P. G., Ascari E. Proliferative activity, response to therapy and survival in multiple myeloma. Haematologica. 1984 Mar-Apr;69(2):148–162. [PubMed] [Google Scholar]
  34. Riccardi A., Ucci G., Luoni R., Castello A., Coci A., Magrini U., Ascari E. Bone marrow biopsy in monoclonal gammopathies: correlations between pathological findings and clinical data. The Cooperative Group for Study and Treatment of Multiple Myeloma. J Clin Pathol. 1990 Jun;43(6):469–475. doi: 10.1136/jcp.43.6.469. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Salmon S. E., Haut A., Bonnet J. D., Amare M., Weick J. K., Durie B. G., Dixon D. O. Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study. J Clin Oncol. 1983 Aug;1(8):453–461. doi: 10.1200/JCO.1983.1.8.453. [DOI] [PubMed] [Google Scholar]
  36. Ucci G., Petrini M., Riccardi A., Invernizzi R., Carulli G., Luoni R., Giordano M., Danova M. Expression of p170 protein in multiple myeloma: a clinical study. Hematol Oncol. 1992 May-Aug;10(3-4):213–220. doi: 10.1002/hon.2900100312. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES